AMSBIO has launched a new range of human exosomes to the regenerative medicine tools and technologies market. Derived from placental and adipose derived stem cells, to ensure consistent high quality, these new products are ideally suited for research involving wound healing, stem cell differentiation and tissue regeneration.
Exosomes are small vesicles (30–150 nm) containing sophisticated RNA and protein cargos. They are secreted by all cell types in culture and are found to occur naturally in body fluids, including blood, saliva, urine, CSF, and breast milk. The precise molecular mechanics for their secretion and uptake, as well as their composition, “cargo”, and resulting functions, are only beginning to be understood.
Exosomes are now viewed as specifically secreted vesicles that enable intercellular communication and have become the focus of rapidly growing interest, both to study their functions and to understand ways to use them in the development of minimally invasive diagnostics. There...
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.